MedTrace Logo

Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

NCT03522688 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2023-07-17

No results posted yet for this study

Summary

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Conditions

Interventions

DRUG

Dexmedetomidine

The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.

DRUG

Normal saline

The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jun-Gol Song, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-11
Primary Completion
2023-07-14
Completion
2024-07-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03522688 on ClinicalTrials.gov